Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88


Independent expansion of epitope-specific plasma cell responses upon HIV-1 envelope glycoprotein immunization.

Forsell MN, Soldemo M, Dosenovic P, Wyatt RT, Karlsson MC, Karlsson Hedestam GB.

J Immunol. 2013 Jul 1;191(1):44-51. doi: 10.4049/jimmunol.1203087. Epub 2013 Jun 5.


Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization.

Dosenovic P, Chakrabarti B, Soldemo M, Douagi I, Forsell MN, Li Y, Phogat A, Paulie S, Hoxie J, Wyatt RT, Karlsson Hedestam GB.

J Immunol. 2009 Sep 1;183(5):3373-82. doi: 10.4049/jimmunol.0900407.


BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses.

Dosenovic P, Soldemo M, Scholz JL, O'Dell S, Grasset EK, Pelletier N, Karlsson MC, Mascola JR, Wyatt RT, Cancro MP, Karlsson Hedestam GB.

J Immunol. 2012 Jun 15;188(12):6018-26. doi: 10.4049/jimmunol.1200466. Epub 2012 May 4.


The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.

Gavioli R, Cellini S, Castaldello A, Voltan R, Gallerani E, Gagliardoni F, Fortini C, Cofano EB, Triulzi C, Cafaro A, Srivastava I, Barnett S, Caputo A, Ensoli B.

Vaccine. 2008 Jan 30;26(5):727-37. Epub 2007 Dec 4.


The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.

Peet NM, McKeating JA, de Souza JB, Roitt IM, Delves PJ, Lund T.

Virology. 1998 Nov 10;251(1):59-70.


HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.

Bower JF, Li Y, Wyatt R, Ross TM.

Vaccine. 2006 Jun 29;24(26):5442-51. Epub 2006 Apr 3.


Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.

Mörner A, Douagi I, Forsell MN, Sundling C, Dosenovic P, O'Dell S, Dey B, Kwong PD, Voss G, Thorstensson R, Mascola JR, Wyatt RT, Karlsson Hedestam GB.

J Virol. 2009 Jan;83(2):540-51. doi: 10.1128/JVI.01102-08. Epub 2008 Nov 12.


A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP.

Virology. 2007 Apr 10;360(2):329-40. Epub 2006 Nov 28.


Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.

Kang CY, Luo L, Wainberg MA, Li Y.

Biol Chem. 1999 Mar;380(3):353-64.


Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.

Someya K, Cecilia D, Ami Y, Nakasone T, Matsuo K, Burda S, Yamamoto H, Yoshino N, Kaizu M, Ando S, Okuda K, Zolla-Pazner S, Yamazaki S, Yamamoto N, Honda M.

J Virol. 2005 Feb;79(3):1452-62.


The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.

de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, Paris RM, Kaewkungwal J, Michael NL, Rerks-Ngarm S, Mathieson B, Marovich M, Currier JR, Kim JH; Ministry of Public Health–Thai AIDS Vaccine Evaluation Group Collaborators.

J Immunol. 2012 May 15;188(10):5166-76. doi: 10.4049/jimmunol.1102756. Epub 2012 Apr 23.


Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.

Richmond JF, Lu S, Santoro JC, Weng J, Hu SL, Montefiori DC, Robinson HL.

J Virol. 1998 Nov;72(11):9092-100.

Supplemental Content

Support Center